Intracellular Delivery III

Market Entry Barriers of Nanomedicines

AvAleš Prokop,Volkmar Weissig

Inbunden, Engelska, 2016

Del i serien Fundamental Biomedical Technologies

1 632 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available.

Produktinformation

Utgivningsdatum:2016-12-23
Mått:155 x 235 x 29 mm
Vikt:948 g
Format:Inbunden
Språk:Engelska
Serie:Fundamental Biomedical Technologies
Antal sidor:453
Upplaga:16001
Förlag:Springer International Publishing AG
ISBN:9783319435237

Utforska kategorier

Onkologi inom Medicin
Teknik: allmänt inom Naturvetenskap och teknik
Cellbiologi inom Naturvetenskap och teknik

Innehållsförteckning

1 Overview of present problems facing commercialization of nanomedicines, Aleš Prokop and Volkmar Weissig.- 2 Precision medicine and site-specific drug delivery, Karel Petrák.- 3 Extracellular matrix degrading enzymes for nanocarrier-based anticancer therapy, Pablo Scodeller.- 4 Nanocarrier-based anticancer therapies with the focus on strategies for targeting the tumor microenvironment, Francisca Leonard and Biana Godin.- 5 New approach to minimize the MPS/RES uptake resulting a reduce toxic side effects of nanodrugs, Li Liu and Chien Ho.- 6 Authentic vascular and stromal structure in animal disease model for nanomedicine, Hiroshi Nishihara and Mitsunobu R Kano.- 7 Ligand-targeted nanocarriers with respect to their translation into the clinic, in particular in comparison with non-targeted nano-medicines, Roy Van der Meel, Laurens J.C. Vehmeijer, Robbert Jan Kok, Gert Storm, Ethlinn V.B. van Gaaland Gert Storm.- 8 Anti-angiogenic therapy by targeting the tumor vasculature with liposomes, Yu Sakurai and Hideyoshi Harashima.- 9 Accessing mitochondrial targets using nanocargos, Ru Wen, Afoma C. Umeano and Shanta Dhar.- 10 Redox-responsive nano-delivery systems for cancer therapy, Amit Singh, Thanh-Huyen Tran and Mansoor M. Amiji.- 11 Nano-emulsions for drug delivery and biomedical imaging, Nicolas Anton, François Hallouard, Mohammed F. Attia and Thierry F. Vandamme.- 12 The tumor microenvironment in nanoparticle delivery and the role of Imaging to navigate roadblocks and pathways, Dmitri Artemov and Zaver M Bhujwalla.- 13 Microscopic mass spectrometry for the precise design of drug delivery systems, Yasuhiro Matsumura and Masahiro Yasunaga.- 14 Pharmacokinetics and pharmacodynamics of nano-drug delivery systems, David Stepensky.- 15 Intracellular drug delivery in PBPK modelling though active and passive transport processes, Lars Kuepfer, Christoph Niederalt, Thomas Wendl, Jan-Frederil Schlender, Michael Block, Thomas Eissing, Donato Teutonic.- 16 Exploitingnanocarriers for combination cancer therapy, Yi Wen Kong, Erik C. Dreaden, Paula T. Hammond and Michael B. Yaffe.- 17 Commercialization of nanotechnology for medical applications, David W. Hobson.- Index